Abstract
Anticancer agents categorized in DDS based on nanotechnology have been approved. Regarding a pipeline of clinical development of micelle carrier system, total 6 clinical trials are now underway not only in Japan but also in other countries.
In this chapter, clinical status of other formulations of DDS as well as micelle carriers will be described. In addition, cancer stromal targeting therapy recently proposed by us will be discussed.